Pulmonx Corporation Common Stock (LUNG)
Pulmonx Corporation develops minimally invasive lung therapies, focusing on bronchoscopic procedures to treat severe emphysema. Its flagship product, Zephyr Endobronchial Valve, is used to improve breathing by reducing lung hyperinflation. The company aims to offer less invasive alternatives to traditional surgery for patients with advanced lung disease.
Company News
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consistin...
Analysts' ratings for Pulmonx (NASDAQ:LUNG) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish B...
Thanks to sales of its Zephyr valve, the company's revenue is growing.